{"disease":{"id":"hypertension","name":"Hypertension","therapeutic_area":"Cardiovascular","data":{"aiSummary":"The treatment landscape for hypertension primarily involves lifestyle modifications and pharmacological interventions. First-line treatments often include calcium channel blockers, ACE inhibitors, ARBs, and thiazide diuretics. Combination therapies are frequently used to achieve blood pressure targets, with fixed-dose combinations becoming increasingly common. Recent advances include the development of novel combination pills and improved patient adherence strategies. The pipeline includes ongoing research into new drug classes and devices for resistant hypertension, aiming to improve blood pressure control and reduce cardiovascular risk.","drug_count":9,"description":"Hypertension is a chronic medical condition characterized by persistently elevated blood pressure in the arteries. It is a major risk factor for cardiovascular diseases, including heart attack, stroke, and kidney failure. Hypertension develops due to a combination of genetic, lifestyle, and environmental factors, leading to increased vascular resistance and cardiac output. Effective management involves lifestyle modifications and, often, pharmacological interventions to reduce blood pressure and minimize the risk of complications.","subtype_count":10},"enrichment_level":2,"last_enriched_at":null,"visit_count":0,"created_at":"2026-03-25T12:16:34.937Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":9,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"treprostinil","indication_name":"Thromboembolic pulmonary hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Remodulin","generic_name":"TREPROSTINIL","company_name":"United Therap","drug_phase":"marketed","molecular_target":"Prostacyclin receptor","drug_class":"Prostacycline Vasodilator [EPC]","quality_score":69,"revenue":"2000","mechanism":"Remodulin works by activating the prostacyclin receptor, which causes blood vessels to relax and widen."},{"drug_id":"treprostinil","indication_name":"Pulmonary arterial hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Remodulin","generic_name":"TREPROSTINIL","company_name":"United Therap","drug_phase":"marketed","molecular_target":"Prostacyclin receptor","drug_class":"Prostacycline Vasodilator [EPC]","quality_score":69,"revenue":"2000","mechanism":"Remodulin works by activating the prostacyclin receptor, which causes blood vessels to relax and widen."},{"drug_id":"sotatercept","indication_name":"pulmonary arterial hypertension (PAH, Group 1 pulmonary hypertension)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Winrevair","generic_name":"SOTATERCEPT","company_name":"Merck Sharp Dohme","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":45,"revenue":"1443","mechanism":"Winrevair works by binding to and inhibiting the activity of activin receptors, which play a role in the development of pulmonary arterial hypertension."},{"drug_id":"sotatercept","indication_name":"pulmonary arterial hypertension (PAH, WHO Group 1 pulmonary hypertension)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Winrevair","generic_name":"SOTATERCEPT","company_name":"Merck Sharp Dohme","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":45,"revenue":"1443","mechanism":"Winrevair works by binding to and inhibiting the activity of activin receptors, which play a role in the development of pulmonary arterial hypertension."},{"drug_id":"macitentan","indication_name":"Pulmonary arterial hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Opsumit","generic_name":"MACITENTAN","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Endothelin-1 receptor","drug_class":"Endothelin Receptor Antagonist [EPC]","quality_score":75,"revenue":"1181.0","mechanism":"Opsumit works by blocking the action of endothelin-1, a protein that causes blood vessels to constrict and increase blood pressure."},{"drug_id":"paclitaxel","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"paclitaxel","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor [EPC]","quality_score":76,"revenue":"368","mechanism":""},{"drug_id":"nab-paclitaxel","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"nab-paclitaxel","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor","quality_score":57,"revenue":"368","mechanism":""},{"drug_id":"nabpaclitaxel","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Taxol","generic_name":"Nabpaclitaxel","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Tubulin beta-3 chain","drug_class":"Microtubule Inhibitor","quality_score":null,"revenue":"368","mechanism":"Taxol works by binding to tubulin and preventing the formation of microtubules, which are essential for cell division."},{"drug_id":"metoprolol","indication_name":"Hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lopressor","generic_name":"metoprolol","company_name":"Generic (originally Ciba-Geigy/Novartis)","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, 5-hydroxytryptamine receptor 1A","drug_class":"Beta-1 selective blocker","quality_score":58,"revenue":null,"mechanism":"Cardioselective beta-1 adrenergic receptor blocker that reduces heart rate, blood pressure, and myocardial oxygen demand."},{"drug_id":"telmisartan","indication_name":"Hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Micardis","generic_name":"TELMISARTAN","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Type-2 angiotensin II receptor","drug_class":"Angiotensin 2 Receptor Blocker [EPC]","quality_score":80,"revenue":null,"mechanism":"Micardis works by blocking the action of angiotensin II, a hormone that constricts blood vessels and increases blood pressure."},{"drug_id":"prazosin","indication_name":"Hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Minipress","generic_name":"PRAZOSIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Alpha-1A adrenergic receptor","drug_class":"alpha-Adrenergic Blocker","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"hydrochlorothiazide","indication_name":"Hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Microzide","generic_name":"hydrochlorothiazide","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"ACE","drug_class":"Thiazide Diuretic [EPC]","quality_score":59,"revenue":null,"mechanism":"Lisinopril inhibits ACE, reducing angiotensin II and aldosterone, leading to lower blood pressure."},{"drug_id":"olmesartan","indication_name":"Hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"olmesartan medoxomil-hydrochlorothiazide","generic_name":"OLMESARTAN","company_name":"Cosette","drug_phase":"marketed","molecular_target":"","drug_class":"Thiazide Diuretic [EPC]","quality_score":60,"revenue":null,"mechanism":"Olmesartan works by blocking the action of a hormone that causes blood vessels to constrict, allowing blood vessels to relax and blood pressure to decrease."},{"drug_id":"prazosin-hydrochloride","indication_name":"Hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PRAZOSIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"moexipril","indication_name":"Hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MOEXIPRIL","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"doxazosin-mesylate","indication_name":"Hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DOXAZOSIN MESYLATE","company_name":"","drug_phase":"marketed","molecular_target":"alpha 1 adrenoceptor","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Doxazosin selectively blocks alpha 1 adrenoceptors, reducing urethral resistance and systemic vascular resistance."},{"drug_id":"moexipril","indication_name":"Hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MOEXIPRIL","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":30,"revenue":null,"mechanism":null},{"drug_id":"candesartan-cilexetil-and-hydrochlorothiazide","indication_name":"Hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Candesartan cilexetil and hydrochlorothiazide","company_name":"Takeda","drug_phase":"marketed","molecular_target":"","drug_class":"Thiazide Diuretic [EPC]","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"torsemide","indication_name":"Hypertension Management","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TORSEMIDE","company_name":"","drug_phase":"marketed","molecular_target":"Na+/K+/2Cl- carrier system","drug_class":"Loop Diuretic [EPC]","quality_score":80,"revenue":null,"mechanism":"Torsemide inhibits the Na+/K+/2Cl- carrier system in the thick ascending limb of the loop of Henle, leading to increased excretion of sodium, chloride, and water."},{"drug_id":"benazepril-hydrochloride","indication_name":"Hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"BENAZEPRIL HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"mecamylamine-hydrochloride","indication_name":"Moderate to severe essential hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MECAMYLAMINE HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"mecamylamine-hydrochloride","indication_name":"Uncomplicated malignant hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MECAMYLAMINE HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"amlodipine-and-olmesartan","indication_name":"Hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"amlodipine and olmesartan","company_name":"InVasc Therapeutics, Inc.","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":18,"revenue":null,"mechanism":null},{"drug_id":"amlodipine-and-olmesartan","indication_name":"Initial Therapy for Hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"amlodipine and olmesartan","company_name":"InVasc Therapeutics, Inc.","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":18,"revenue":null,"mechanism":null},{"drug_id":"terazosin-hydrochloride","indication_name":"Hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TERAZOSIN HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":20,"revenue":null,"mechanism":null},{"drug_id":"irbesartan-and-hydrochlorothiazide","indication_name":"Hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Irbesartan and Hydrochlorothiazide","company_name":"Roxane Laboratories","drug_phase":"marketed","molecular_target":"AT1 angiotensin II receptor","drug_class":"Thiazide Diuretic [EPC]","quality_score":60,"revenue":null,"mechanism":"Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by binding to the AT1 receptor."},{"drug_id":"irbesartan-and-hydrochlorothiazide","indication_name":"Initial Therapy for Hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Irbesartan and Hydrochlorothiazide","company_name":"Roxane Laboratories","drug_phase":"marketed","molecular_target":"AT1 angiotensin II receptor","drug_class":"Thiazide Diuretic [EPC]","quality_score":60,"revenue":null,"mechanism":"Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by binding to the AT1 receptor."},{"drug_id":"caduet","indication_name":"Hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Caduet","generic_name":"Amlodipine Besylate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channel","drug_class":"Dihydropyridine calcium channel blocker","quality_score":76,"revenue":null,"mechanism":"Calcium channel antagonist inhibiting transmembrane calcium influx into vascular and cardiac muscle."},{"drug_id":"chlorothiazide","indication_name":"Hypertension with Left Ventricular Hypertrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diuril","generic_name":"CHLOROTHIAZIDE","company_name":"Salix Pharms","drug_phase":"marketed","molecular_target":"Solute carrier family 12 member 3","drug_class":"Thiazide Diuretic","quality_score":51,"revenue":null,"mechanism":""},{"drug_id":"esaxerenone","indication_name":"Hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Minnebro","generic_name":"esaxerenone","company_name":"Daiichi Sankyo","drug_phase":"marketed","molecular_target":"Mineralocorticoid receptor","drug_class":"","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"alacepril","indication_name":"Essential hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cetapril","generic_name":"ALACEPRIL","company_name":"Par Pharm","drug_phase":"marketed","molecular_target":"Angiotensin-converting enzyme","drug_class":"Angiotensin Converting Enzyme Inhibitor","quality_score":21,"revenue":null,"mechanism":""},{"drug_id":"brimonidine-tartrate","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alphagan","generic_name":"BRIMONIDINE TARTRATE","company_name":"Senju Pharmaceutical Co., Ltd","drug_phase":"marketed","molecular_target":"Alpha-2C adrenergic receptor","drug_class":"alpha-Adrenergic Agonist","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"tadalafil","indication_name":"Pulmonary hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cialis","generic_name":"tadalafil","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 2 group E member 1, Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, Potassium voltage-gated channel subfamily H member 2","drug_class":"Phosphodiesterase 5 Inhibitor [EPC]","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"dorzolamide","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trusopt","generic_name":"DORZOLAMIDE","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 2","drug_class":"Carbonic Anhydrase Inhibitor","quality_score":51,"revenue":null,"mechanism":"Trusopt works by inhibiting the enzyme carbonic anhydrase 2, which is involved in the production of aqueous humor in the eye."},{"drug_id":"levobunolol","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betagan","generic_name":"LEVOBUNOLOL","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"Beta-2 adrenergic receptor","drug_class":"beta-Adrenergic Blocker","quality_score":46,"revenue":null,"mechanism":""},{"drug_id":"brimonidine","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Alphagan","generic_name":"BRIMONIDINE","company_name":"Senju Pharmaceutical Co., Ltd","drug_phase":"marketed","molecular_target":"Alpha-2C adrenergic receptor","drug_class":"alpha-Adrenergic Agonist","quality_score":46,"revenue":null,"mechanism":""},{"drug_id":"nitric-oxide","indication_name":"Persistent pulmonary hypertension of the newborn","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inomax","generic_name":"NITRIC OXIDE","company_name":"Vero Biotech Inc","drug_phase":"marketed","molecular_target":"Soluble guanylate cyclase","drug_class":"Standardized Chemical Allergen [EPC]","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"nitric-oxide","indication_name":"Pulmonary hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inomax","generic_name":"NITRIC OXIDE","company_name":"Vero Biotech Inc","drug_phase":"marketed","molecular_target":"Soluble guanylate cyclase","drug_class":"Standardized Chemical Allergen [EPC]","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"levobetaxolol","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betaxon","generic_name":"LEVOBETAXOLOL","company_name":"Alcon Pharms Ltd","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"levobetaxolol","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"fenoldopam","indication_name":"Malignant essential hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Corlopam","generic_name":"FENOLDOPAM","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"D(1A) dopamine receptor","drug_class":"Dopaminergic Agonist","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"bosentan","indication_name":"Pulmonary arterial hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tracleer","generic_name":"BOSENTAN","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Endothelin-1 receptor","drug_class":"Endothelin Receptor Antagonist","quality_score":52,"revenue":null,"mechanism":""},{"drug_id":"bosentan","indication_name":"Pulmonary hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tracleer","generic_name":"BOSENTAN","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Endothelin-1 receptor","drug_class":"Endothelin Receptor Antagonist","quality_score":52,"revenue":null,"mechanism":""},{"drug_id":"glyceryl-trinitrate","indication_name":"Perioperative hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nitroglycerin","generic_name":"glyceryl trinitrate","company_name":"Fougera","drug_phase":"marketed","molecular_target":"guanylate cyclase","drug_class":"Nitrate Vasodilator [EPC]","quality_score":65,"revenue":null,"mechanism":"Nitroglycerin forms nitric oxide, activating guanylate cyclase and increasing cyclic GMP, leading to smooth muscle relaxation and vasodilation."},{"drug_id":"losartan-potassium","indication_name":"Hypertension with Left Ventricular Hypertrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cozaar","generic_name":"LOSARTAN POTASSIUM","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Type-1 angiotensin II receptor","drug_class":"Angiotensin 2 Receptor Blocker","quality_score":69,"revenue":null,"mechanism":"Cozaar works by blocking the action of angiotensin II on its receptor, which helps to relax blood vessels and lower blood pressure."},{"drug_id":"esmolol","indication_name":"Perioperative hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brevibloc In Plastic Container","generic_name":"ESMOLOL","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"beta-Adrenergic Blocker","quality_score":63,"revenue":null,"mechanism":"Brevibloc works by blocking the beta-1 adrenergic receptor, which reduces the heart's response to stress and increases heart rate."},{"drug_id":"prazosin-hcl","indication_name":"Hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prazosin Hcl","generic_name":"prazosin-hcl","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 1D","drug_class":"prazosin","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"aldactone","indication_name":"Hypertension as add-on therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aldactone","generic_name":"Spironolactone","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Aldosterone receptors at aldosterone-dependent sodium-potassium exchange site in distal convoluted renal tubule","drug_class":"Potassium-sparing diuretic, aldosterone antagonist","quality_score":66,"revenue":null,"mechanism":"Aldosterone antagonist causing increased sodium and water excretion while retaining potassium."},{"drug_id":"verapamil-hydrochloride","indication_name":"Essential hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Verapamil Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channels (slow channels)","drug_class":"Calcium channel blocker","quality_score":56,"revenue":null,"mechanism":"Calcium ion influx inhibitor that modulates ionic calcium across cell membranes of arterial smooth muscle and myocardial cells."},{"drug_id":"moxonidin","indication_name":"Essential hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Moxonidin","company_name":"University of Aarhus","drug_phase":"discontinued","molecular_target":"5-hydroxytryptamine receptor 1A, Alpha-2A adrenergic receptor, Alpha-2C adrenergic receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"prostacyclin","indication_name":"Pulmonary arterial hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prostacyclin","company_name":"United Therapeutics","drug_phase":"marketed","molecular_target":"P2Y purinoceptor 12, Prostacyclin receptor, Prostaglandin E2 receptor EP1 subtype","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"prostacyclin","indication_name":"Pulmonary hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prostacyclin","company_name":"United Therapeutics","drug_phase":"marketed","molecular_target":"P2Y purinoceptor 12, Prostacyclin receptor, Prostaglandin E2 receptor EP1 subtype","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"brevibloc","indication_name":"Perioperative hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Brevibloc","company_name":"AOP Orphan Pharmaceuticals AG","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor, Beta-1 adrenergic receptor, Beta-2 adrenergic receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"ilomedin","indication_name":"Pulmonary arterial hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ilomedin","company_name":"Prim PD Dr Afshin Assadian","drug_phase":"phase_2","molecular_target":"Prostacyclin receptor, Prostaglandin D2 receptor, Prostaglandin E2 receptor EP1 subtype","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"azopt","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Azopt","company_name":"Alcon Research","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 1, Carbonic anhydrase 12, Carbonic anhydrase 13","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"mannitol-20","indication_name":"Benign intracranial hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mannitol","generic_name":"Mannitol","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Glomerular filtrate osmolarity; intracellular water movement","drug_class":"Osmotic diuretic","quality_score":66,"revenue":null,"mechanism":"Osmotic diuretic that elevates glomerular filtrate osmolarity to inhibit tubular water reabsorption."},{"drug_id":"mannitol-20","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mannitol","generic_name":"Mannitol","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Glomerular filtrate osmolarity; intracellular water movement","drug_class":"Osmotic diuretic","quality_score":66,"revenue":null,"mechanism":"Osmotic diuretic that elevates glomerular filtrate osmolarity to inhibit tubular water reabsorption."},{"drug_id":"cialis","indication_name":"Pulmonary hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cialis","company_name":"Ottawa Hospital Research Institute","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 2 group E member 1, Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, Potassium voltage-gated channel subfamily H member 2","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"nitrogen-nf","indication_name":"Persistent pulmonary hypertension of the newborn","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"NITROGEN, NF","generic_name":"NITROGEN, NF","company_name":"UNIVERSAL INDUSTRIAL GASES, INC","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":16,"revenue":null,"mechanism":""},{"drug_id":"adempas","indication_name":"Chronic thromboembolic pulmonary hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adempas","company_name":"University of Colorado, Denver","drug_phase":"marketed","molecular_target":"Guanylate cyclase soluble subunit beta-1, cAMP-specific 3',5'-cyclic phosphodiesterase 7B","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"adempas","indication_name":"Pulmonary arterial hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adempas","company_name":"University of Colorado, Denver","drug_phase":"marketed","molecular_target":"Guanylate cyclase soluble subunit beta-1, cAMP-specific 3',5'-cyclic phosphodiesterase 7B","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"befunolol","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bentos","generic_name":"BEFUNOLOL","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"befunolol","quality_score":null,"revenue":null,"mechanism":"Bentos works by reducing the production of fluid in the eye, thereby lowering intraocular pressure."},{"drug_id":"benzylhydrochlorothiazide","indication_name":"Malignant hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Behyd","generic_name":"benzylhydrochlorothiazide","company_name":"","drug_phase":"unknown","molecular_target":"","drug_class":"","quality_score":null,"revenue":null,"mechanism":"Behyd works by blocking sodium reabsorption in the kidneys, which increases urine production and reduces blood pressure."},{"drug_id":"tilisolol","indication_name":"Essential hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Selecal","generic_name":"TILISOLOL","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"tilisolol","quality_score":null,"revenue":null,"mechanism":"Selecal works by blocking beta-1 adrenergic receptors in the heart, reducing heart rate and blood pressure."},{"drug_id":"moxonidine","indication_name":"Essential hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Moxonidin","generic_name":"MOXONIDINE","company_name":"","drug_phase":"marketed","molecular_target":"Nischarin","drug_class":"moxonidine","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"isobide","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Isobide","company_name":"Alvogen Korea","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":9,"revenue":null,"mechanism":null},{"drug_id":"metipranolol","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Optipranolol","generic_name":"METIPRANOLOL","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"beta-Adrenergic Blocker","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"brinzolamide","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azopt","generic_name":"BRINZOLAMIDE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"carbonic anhydrase II","drug_class":"Carbonic Anhydrase Inhibitor [EPC]","quality_score":48,"revenue":null,"mechanism":"Brinzolamide reduces intraocular pressure by inhibiting carbonic anhydrase II, decreasing aqueous humor secretion."},{"drug_id":"hydrochlorothiazide","indication_name":"Hypertension with Left Ventricular Hypertrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Microzide","generic_name":"hydrochlorothiazide","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"ACE","drug_class":"Thiazide Diuretic [EPC]","quality_score":59,"revenue":null,"mechanism":"Lisinopril inhibits ACE, reducing angiotensin II and aldosterone, leading to lower blood pressure."},{"drug_id":"xalatan","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xalatan","company_name":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","drug_phase":"marketed","molecular_target":"Prostaglandin E2 receptor EP1 subtype, Prostaglandin E2 receptor EP3 subtype, Prostaglandin F2-alpha receptor","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"beraprost","indication_name":"Pulmonary arterial hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Procylin","generic_name":"BERAPROST","company_name":"","drug_phase":"discontinued","molecular_target":"Prostacyclin receptor","drug_class":"beraprost","quality_score":null,"revenue":null,"mechanism":"Procylin works by activating the prostacyclin receptor, which helps to relax blood vessels and improve blood flow."},{"drug_id":"revatio","indication_name":"Pulmonary arterial hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Revatio","generic_name":"Sildenafil Citrate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Phosphodiesterase type 5 (PDE5)","drug_class":"PDE5 inhibitor","quality_score":66,"revenue":null,"mechanism":"Sildenafil inhibits phosphodiesterase type 5 (PDE5), increasing cGMP levels and enabling penile smooth muscle relaxation."},{"drug_id":"losartan","indication_name":"Hypertension with Left Ventricular Hypertrophy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cozaar","generic_name":"losartan","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"AT1 receptor","drug_class":"ARB (Angiotensin II receptor blocker)","quality_score":65,"revenue":null,"mechanism":"Losartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively binding to the AT1 receptor."},{"drug_id":"latanoprost","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xalatan","generic_name":"LATANOPROST","company_name":"Thea Pharma","drug_phase":"marketed","molecular_target":"Prostaglandin F2-alpha receptor","drug_class":"Prostaglandin Analog [EPC]","quality_score":75,"revenue":null,"mechanism":"Xalatan works by increasing the outflow of fluid from the eye, reducing pressure."},{"drug_id":"travoprost","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Travatan","generic_name":"TRAVOPROST","company_name":"","drug_phase":"marketed","molecular_target":"Prostaglandin F2-alpha receptor","drug_class":"Prostaglandin Analog [EPC]","quality_score":70,"revenue":null,"mechanism":"Travatan works by increasing the outflow of fluid from the eye to reduce pressure."},{"drug_id":"bimatoprost","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lumigan","generic_name":"BIMATOPROST","company_name":"","drug_phase":"marketed","molecular_target":"Aldo-keto reductase family 1 member C3","drug_class":"Prostaglandin Analog [EPC]","quality_score":75,"revenue":null,"mechanism":"Lumigan works by increasing the outflow of fluid from the eye to reduce pressure."},{"drug_id":"epoprostenol","indication_name":"Pulmonary arterial hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Flolan","generic_name":"EPOPROSTENOL","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Prostacyclin receptor","drug_class":"Prostacycline Vasodilator [EPC]","quality_score":75,"revenue":null,"mechanism":"Flolan works by binding to the prostacyclin receptor, causing blood vessels to relax and dilate."},{"drug_id":"epoprostenol","indication_name":"Pulmonary hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Flolan","generic_name":"EPOPROSTENOL","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Prostacyclin receptor","drug_class":"Prostacycline Vasodilator [EPC]","quality_score":75,"revenue":null,"mechanism":"Flolan works by binding to the prostacyclin receptor, causing blood vessels to relax and dilate."},{"drug_id":"carteolol","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ocupress","generic_name":"CARTEOLOL","company_name":"","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"beta-Adrenergic Blocker","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"ambrisentan","indication_name":"Pulmonary arterial hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Letairis","generic_name":"AMBRISENTAN","company_name":"Gilead Sciences","drug_phase":"marketed","molecular_target":"Endothelin-1 receptor","drug_class":"Endothelin Receptor Antagonist [EPC]","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"isosorbide","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isobide","generic_name":"ISOSORBIDE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"","drug_class":"Nitrate Vasodilator [EPC]","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"olmesartan","indication_name":"hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"olmesartan medoxomil-hydrochlorothiazide","generic_name":"OLMESARTAN","company_name":"Cosette","drug_phase":"marketed","molecular_target":"","drug_class":"Thiazide Diuretic [EPC]","quality_score":60,"revenue":null,"mechanism":"Olmesartan works by blocking the action of a hormone that causes blood vessels to constrict, allowing blood vessels to relax and blood pressure to decrease."},{"drug_id":"tolazoline","indication_name":"Persistent pulmonary hypertension of the newborn","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vasodil","generic_name":"TOLAZOLINE","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Alpha-2A adrenergic receptor","drug_class":"tolazoline","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"nitroprusside","indication_name":"Malignant essential hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sodium Nitroprusside","generic_name":"NITROPRUSSIDE","company_name":"Roche","drug_phase":"marketed","molecular_target":"Atrial natriuretic peptide receptor 1","drug_class":"Vasodilator","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"verapamil-hydrochloride","indication_name":"Essential hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Verapamil Hydrochloride","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channels (slow channels)","drug_class":"Calcium channel blocker","quality_score":56,"revenue":null,"mechanism":"Calcium ion influx inhibitor that modulates ionic calcium across cell membranes of arterial smooth muscle and myocardial cells."},{"drug_id":"hctz","indication_name":"hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lisinopril/HCTZ","generic_name":"HCTZ","company_name":"Direct_Rx","drug_phase":"marketed","molecular_target":"","drug_class":"Thiazide Diuretic [EPC]","quality_score":47,"revenue":null,"mechanism":""},{"drug_id":"bunazosin","indication_name":"Essential hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Detantol","generic_name":"BUNAZOSIN","company_name":"","drug_phase":"phase_3","molecular_target":"Alpha-1A adrenergic receptor","drug_class":"bunazosin","quality_score":null,"revenue":null,"mechanism":"Detanidol works by blocking the alpha-1A adrenergic receptor, which helps to relax blood vessels and lower blood pressure."},{"drug_id":"pilocarpine","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Salagen","generic_name":"PILOCARPINE","company_name":"","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M4","drug_class":"Cholinergic Receptor Agonist","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"latanoprostene-bunod","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vyzulta","generic_name":"LATANOPROSTENE BUNOD","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Prostaglandin F2-alpha receptor","drug_class":"","quality_score":70,"revenue":null,"mechanism":"Vyzulta works by activating the Prostaglandin F2-alpha receptor, which increases the outflow of aqueous humor from the eye, thereby reducing intraocular pressure."},{"drug_id":"mannitol","indication_name":"Benign intracranial hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aridol Kit","generic_name":"MANNITOL","company_name":"Baxter","drug_phase":"marketed","molecular_target":"sodium channels","drug_class":"Osmotic Diuretic [EPC]","quality_score":75,"revenue":null,"mechanism":"Mannitol works by drawing water into the bloodstream from surrounding tissues, increasing urine production and reducing fluid accumulation in the body."},{"drug_id":"mannitol","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aridol Kit","generic_name":"MANNITOL","company_name":"Baxter","drug_phase":"marketed","molecular_target":"sodium channels","drug_class":"Osmotic Diuretic [EPC]","quality_score":75,"revenue":null,"mechanism":"Mannitol works by drawing water into the bloodstream from surrounding tissues, increasing urine production and reducing fluid accumulation in the body."},{"drug_id":"netarsudil","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rhopressa","generic_name":"NETARSUDIL","company_name":"Alcon Labs Inc","drug_phase":"marketed","molecular_target":"rho kinase","drug_class":"Rho Kinase Inhibitor","quality_score":70,"revenue":null,"mechanism":"Netarsudil reduces intraocular pressure by increasing aqueous humor outflow through the trabecular meshwork."},{"drug_id":"selexipag","indication_name":"Pulmonary arterial hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Uptravi","generic_name":"SELEXIPAG","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Prostacyclin receptor","drug_class":"Prostacyclin Receptor Agonist [EPC]","quality_score":70,"revenue":null,"mechanism":"Uptravi works by activating the prostacyclin receptor, which helps to relax blood vessels and improve blood flow."},{"drug_id":"selexipag","indication_name":"Thromboembolic pulmonary hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Uptravi","generic_name":"SELEXIPAG","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Prostacyclin receptor","drug_class":"Prostacyclin Receptor Agonist [EPC]","quality_score":70,"revenue":null,"mechanism":"Uptravi works by activating the prostacyclin receptor, which helps to relax blood vessels and improve blood flow."},{"drug_id":"betaxolol","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betoptic","generic_name":"BETAXOLOL","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"beta-Adrenergic Blocker","quality_score":80,"revenue":null,"mechanism":"Betaxolol works by blocking the beta-1 adrenergic receptor in the heart and eyes, reducing heart rate and pressure, and decreasing intraocular pressure."},{"drug_id":"aprocitentan","indication_name":"Hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tryvio","generic_name":"APROCITENTAN","company_name":"Idorsia","drug_phase":"marketed","molecular_target":"","drug_class":"Endothelin Receptor Antagonist [EPC]","quality_score":60,"revenue":null,"mechanism":"Tryvio works by blocking the action of endothelin, a protein that constricts blood vessels and increases blood pressure."},{"drug_id":"thiopental","indication_name":"Benign intracranial hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pentothal","generic_name":"THIOPENTAL","company_name":"Abbott","drug_phase":"marketed","molecular_target":"GABA-A receptor alpha-1/beta-2/gamma-2","drug_class":"thiopental","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"torsemide","indication_name":"Hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TORSEMIDE","company_name":"","drug_phase":"marketed","molecular_target":"Na+/K+/2Cl- carrier system","drug_class":"Loop Diuretic [EPC]","quality_score":80,"revenue":null,"mechanism":"Torsemide inhibits the Na+/K+/2Cl- carrier system in the thick ascending limb of the loop of Henle, leading to increased excretion of sodium, chloride, and water."},{"drug_id":"riociguat","indication_name":"Chronic thromboembolic pulmonary hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Adempas","generic_name":"RIOCIGUAT","company_name":"Bayer","drug_phase":"marketed","molecular_target":"Guanylate cyclase soluble subunit beta-1","drug_class":"Soluble Guanylate Cyclase Stimulator [EPC]","quality_score":80,"revenue":null,"mechanism":"Adempas works by stimulating the soluble guanylate cyclase enzyme to increase levels of cyclic guanosine monophosphate (cGMP), a signaling molecule that helps to relax blood vessels."},{"drug_id":"riociguat","indication_name":"Pulmonary arterial hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Adempas","generic_name":"RIOCIGUAT","company_name":"Bayer","drug_phase":"marketed","molecular_target":"Guanylate cyclase soluble subunit beta-1","drug_class":"Soluble Guanylate Cyclase Stimulator [EPC]","quality_score":80,"revenue":null,"mechanism":"Adempas works by stimulating the soluble guanylate cyclase enzyme to increase levels of cyclic guanosine monophosphate (cGMP), a signaling molecule that helps to relax blood vessels."},{"drug_id":"chlorthalidone","indication_name":"Hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CHLORTHALIDONE","company_name":"","drug_phase":"marketed","molecular_target":"Na+/Cl− cotransporter","drug_class":"Thiazide-like Diuretic [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"sitaxsentan","indication_name":"Pulmonary arterial hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Sitaxsentan","company_name":"Pfizer","drug_phase":"discontinued","molecular_target":"Endothelin B receptor, Endothelin-1 receptor, Endothelin-1 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"glanatec","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Glanatec","company_name":"Michael D. Straiko, MD","drug_phase":"phase_2","molecular_target":"Serine/threonine-protein kinase TAO3, 5'-AMP-activated protein kinase subunit gamma-1, Aurora kinase B","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"travatan","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Travatan","company_name":"Alcon Research","drug_phase":"marketed","molecular_target":"Prostaglandin E2 receptor EP3 subtype, Prostaglandin F2-alpha receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"abraxane","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Abraxane","company_name":"The First Affiliated Hospital with Nanjing Medical University","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 7, Bile salt export pump, Melanocortin receptor 5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"nitroglycerine","indication_name":"Perioperative hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"nitroglycerine","company_name":"University Hospital, Ghent","drug_phase":"marketed","molecular_target":"Atrial natriuretic peptide receptor 1, Soluble guanylate cyclase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ventavis","indication_name":"Pulmonary arterial hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ventavis","company_name":"Meshalkin Research Institute of Pathology of Circulation","drug_phase":"phase_2","molecular_target":"Prostacyclin receptor, Prostaglandin D2 receptor, Prostaglandin E2 receptor EP1 subtype","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"salagen","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Salagen","company_name":"Alberta Health services","drug_phase":"marketed","molecular_target":"Muscarinic acetylcholine receptor M1, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M3","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"taxol","indication_name":"Ocular hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Taxol","company_name":"M.D. Anderson Cancer Center","drug_phase":"marketed","molecular_target":"Multidrug resistance-associated protein 7, Bile salt export pump, Melanocortin receptor 5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"sildenafil","indication_name":"Pulmonary arterial hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Viagra","generic_name":"sildenafil","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, High affinity cGMP-specific 3',5'-cyclic phosphodiesterase 9A, Multidrug resistance-associated protein 5","drug_class":"PDE5 inhibitor","quality_score":null,"revenue":null,"mechanism":"Selectively inhibits phosphodiesterase type 5 (PDE5), increasing cGMP levels to relax smooth muscle in the corpus cavernosum and pulmonary vasculature."},{"drug_id":"cilexetil","indication_name":"Hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Candesartan Cilexetil","generic_name":"CILEXETIL","company_name":"Alembic","drug_phase":"marketed","molecular_target":"Ace Inhibitor","drug_class":"","quality_score":60,"revenue":null,"mechanism":"Candesartan cilexetil works by blocking the action of angiotensin II, a hormone that constricts blood vessels, to lower blood pressure and improve heart function."},{"drug_id":"mecamylamine","indication_name":"Moderately severe to severe essential hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inversine","generic_name":"MECAMYLAMINE","company_name":"","drug_phase":"marketed","molecular_target":"Neuronal acetylcholine receptor; alpha3/beta2","drug_class":"Autonomic Ganglionic Blocker","quality_score":48,"revenue":null,"mechanism":""},{"drug_id":"mecamylamine","indication_name":"Uncomplicated malignant hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inversine","generic_name":"MECAMYLAMINE","company_name":"","drug_phase":"marketed","molecular_target":"Neuronal acetylcholine receptor; alpha3/beta2","drug_class":"Autonomic Ganglionic Blocker","quality_score":48,"revenue":null,"mechanism":""},{"drug_id":"nicardipine-hydrochloride","indication_name":"Hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"NICARDIPINE HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"Calcium ion channels","drug_class":"Calcium channel blocker","quality_score":53,"revenue":null,"mechanism":"Nicardipine blocks calcium ion influx into vascular smooth muscle, causing relaxation with minimal effect on cardiac muscle."},{"drug_id":"fosinopril","indication_name":"Hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Monopril","generic_name":"FOSINOPRIL","company_name":"","drug_phase":"marketed","molecular_target":"Angiotensin-converting enzyme","drug_class":"Angiotensin Converting Enzyme Inhibitor","quality_score":64,"revenue":null,"mechanism":"Monopril works by blocking the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor."},{"drug_id":"sotatercept-csrk","indication_name":"Pulmonary Arterial Hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"WINREVAIR","generic_name":"SOTATERCEPT-CSRK","company_name":"MERCK SHARP DOHME","drug_phase":"marketed","molecular_target":"activin A and other TGF-β superfamily ligands","drug_class":"","quality_score":46,"revenue":null,"mechanism":"Sotatercept-csrk binds to activin A and other TGF-β superfamily ligands, improving the balance between pro-proliferative and anti-proliferative signaling to modulate vascular proliferation."},{"drug_id":"esmolol","indication_name":"Control of perioperative tachycardia and hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brevibloc In Plastic Container","generic_name":"ESMOLOL","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Beta-1 adrenergic receptor","drug_class":"beta-Adrenergic Blocker","quality_score":63,"revenue":null,"mechanism":"Brevibloc works by blocking the beta-1 adrenergic receptor, which reduces the heart's response to stress and increases heart rate."},{"drug_id":"enalapril-maleate","indication_name":"Hypertension","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vasotec","generic_name":"ENALAPRIL MALEATE","company_name":"Azurity","drug_phase":"marketed","molecular_target":"Angiotensin-converting enzyme","drug_class":"Angiotensin Converting Enzyme Inhibitor","quality_score":67,"revenue":null,"mechanism":"Vasotec works by blocking the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor."}],"pipeline":[{"drug_id":"torsemide","indication_name":"Postpartum hypertension","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TORSEMIDE","company_name":"","drug_phase":"marketed","molecular_target":"Na+/K+/2Cl- carrier system","drug_class":"Loop Diuretic [EPC]","quality_score":80,"revenue":null,"mechanism":"Torsemide inhibits the Na+/K+/2Cl- carrier system in the thick ascending limb of the loop of Henle, leading to increased excretion of sodium, chloride, and water."},{"drug_id":"chlorthalidone","indication_name":"Efficacy and safety of olmesartan associated with chlorthalidone in essential arterial hypertension","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CHLORTHALIDONE","company_name":"","drug_phase":"marketed","molecular_target":"Na+/Cl− cotransporter","drug_class":"Thiazide-like Diuretic [EPC]","quality_score":65,"revenue":null,"mechanism":""}],"offLabel":[],"totalMarketed":117,"totalPipeline":2},"trials":{"data":[{"nct_id":"NCT06964217","title":"Immediate Fracture Risk After Antihypertensive Drug Initiation","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":10000000,"lead_sponsor_name":"Ajou University School of Medicine","has_results":false},{"nct_id":"NCT03847753","title":"Exploring the Comorbidity Between Mental Disorders and General Medical Conditions","phase":"","overall_status":"COMPLETED","enrollment_count":5940299,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT06517134","title":"Prescribing Patterns of Antihypertensive Drugs in Uncomplicated Hypertension","phase":"","overall_status":"COMPLETED","enrollment_count":3325032,"lead_sponsor_name":"University Hospital, Caen","has_results":false},{"nct_id":"NCT06239129","title":"The Stockholm CREAtinine Measurements Project","phase":"","overall_status":"COMPLETED","enrollment_count":3200000,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT04334824","title":"Hydrochlorothiazide and Risk of Skin Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":2953748,"lead_sponsor_name":"Canadian Network for Observational Drug Effect Studies, CNODES","has_results":false},{"nct_id":"NCT05285085","title":"Real World Evidence Study of Statin Use in Brazil","phase":"","overall_status":"COMPLETED","enrollment_count":2133900,"lead_sponsor_name":"Hospital Israelita Albert Einstein","has_results":false},{"nct_id":"NCT03545763","title":"Evaluating Control of Hypertension - Effect of Social Determinants","phase":"","overall_status":"COMPLETED","enrollment_count":1939783,"lead_sponsor_name":"Oregon Health and Science University","has_results":false},{"nct_id":"NCT07126041","title":"Scalable Public Health Empowerment, Research, and Education Sites (SPHERES)","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":1750000,"lead_sponsor_name":"Oxford University Clinical Research Unit Indonesia","has_results":false},{"nct_id":"NCT03818659","title":"Improving BP Control in Diverse Populations Using BP MAP","phase":"NA","overall_status":"COMPLETED","enrollment_count":1238835,"lead_sponsor_name":"University of California, San Francisco","has_results":true},{"nct_id":"NCT06415071","title":"Hypertension Longitudinal Data Platform in Tianjin","phase":"","overall_status":"COMPLETED","enrollment_count":1172280,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT05506800","title":"Guangzhou Women's Health Cohort Study (GWHCS)","phase":"","overall_status":"SUSPENDED","enrollment_count":1000000,"lead_sponsor_name":"Guangzhou Women and Children's Medical Center","has_results":false},{"nct_id":"NCT05015049","title":"Hypertensive Disorders of Pregnancy - the Neonatal Burden of Disease","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":823957,"lead_sponsor_name":"Imperial College London","has_results":false},{"nct_id":"NCT05794997","title":"Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Propranolol/Carvedilol Versus Atenolol/Bisoprolol/Sotalol","phase":"","overall_status":"COMPLETED","enrollment_count":817337,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":true},{"nct_id":"NCT03954119","title":"Blood Pressure in the Emergency Department","phase":"","overall_status":"COMPLETED","enrollment_count":300272,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT05810545","title":"Drinking Water PFAS, Pregnancy Outcome and Maternal Morbidity","phase":"","overall_status":"COMPLETED","enrollment_count":256659,"lead_sponsor_name":"Karolinska Institutet","has_results":false},{"nct_id":"NCT06622304","title":"Exploring the Effects of Antihypertensive and Lipid-Lowering Drugs on Inflammatory Cytokine Levels","phase":"","overall_status":"COMPLETED","enrollment_count":250736,"lead_sponsor_name":"Guangzhou Institute of Respiratory Disease","has_results":false},{"nct_id":"NCT05248412","title":"The Long-term Spill-over Impact of COVID-19 on Health and Healthcare of People With Non-communicable Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":250000,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT03987633","title":"EMPOWER-1: A Multi-site Clinical Cohort Research Study to Reduce Health Inequality","phase":"","overall_status":"RECRUITING","enrollment_count":200000,"lead_sponsor_name":"Future Genetics Limited","has_results":false},{"nct_id":"NCT04289701","title":"Hypertension Registry of \"Hypertension Prevention and Control Initiative in China\"","phase":"","overall_status":"UNKNOWN","enrollment_count":200000,"lead_sponsor_name":"Chinese Academy of Medical Sciences, Fuwai Hospital","has_results":false},{"nct_id":"NCT05125224","title":"Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Dihydropyridine Calcium Channel Blockers Versus Hydrochlorothiazide","phase":"","overall_status":"COMPLETED","enrollment_count":163720,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":true},{"nct_id":"NCT03301194","title":"Cost-effectiveness of RAMP-HT for Patients With Uncontrolled Hypertension in Hong Kong","phase":"","overall_status":"COMPLETED","enrollment_count":158322,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT05125237","title":"Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Amiloride vs Triamterene","phase":"","overall_status":"COMPLETED","enrollment_count":155963,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":true},{"nct_id":"NCT06930989","title":"Primary Prevention Long-term Registry Study in OSA and Hypertension. Survival Analysis 2010-2022","phase":"","overall_status":"COMPLETED","enrollment_count":148467,"lead_sponsor_name":"Vastra Gotaland Region","has_results":false},{"nct_id":"NCT04662203","title":"Can Frailty Inform the Management of Hypertension in Older People?","phase":"","overall_status":"UNKNOWN","enrollment_count":145598,"lead_sponsor_name":"University of Leeds","has_results":false},{"nct_id":"NCT03106727","title":"Evaluating the Impact of a Community Health Worker Program in Neno, Malawi","phase":"NA","overall_status":"COMPLETED","enrollment_count":122395,"lead_sponsor_name":"Partners in Health","has_results":false},{"nct_id":"NCT03760562","title":"The Risk of Hypertension Associated With Oral Glucocorticoids in Chronic Inflammatory Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":111804,"lead_sponsor_name":"University of Leeds","has_results":false},{"nct_id":"NCT04791046","title":"Antihypertensive Therapy in Patients With Comorbidities","phase":"","overall_status":"UNKNOWN","enrollment_count":100000,"lead_sponsor_name":"Center of Personalized Medicine, Pirogova","has_results":false},{"nct_id":"NCT04182503","title":"Environmental Factors and Embryonic Development Project","phase":"","overall_status":"UNKNOWN","enrollment_count":100000,"lead_sponsor_name":"Jinling Hospital, China","has_results":false},{"nct_id":"NCT04302974","title":"Cohort Study on Patient Outcomes, Effectiveness and Cost-effectiveness of Intervention Programmes for DM/HT Patients","phase":"","overall_status":"COMPLETED","enrollment_count":100000,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT04229628","title":"Hypertension and Diabetes Mellitus Community Management Center(HAD-COME) Project","phase":"","overall_status":"UNKNOWN","enrollment_count":100000,"lead_sponsor_name":"Guangdong Provincial People's Hospital","has_results":false},{"nct_id":"NCT03285230","title":"The French E3N Prospective Cohort Study","phase":"","overall_status":"UNKNOWN","enrollment_count":100000,"lead_sponsor_name":"Institut National de la Santé Et de la Recherche Médicale, France","has_results":false},{"nct_id":"NCT05609513","title":"Integration of Hypertension Management in HIV Care in Uganda","phase":"NA","overall_status":"COMPLETED","enrollment_count":87421,"lead_sponsor_name":"Infectious Diseases Research Collaboration, Uganda","has_results":false},{"nct_id":"NCT03677609","title":"Stanford Clinics Physician Mindset Training","phase":"NA","overall_status":"COMPLETED","enrollment_count":78128,"lead_sponsor_name":"Kari Alyse Leibowitz","has_results":false},{"nct_id":"NCT07436104","title":"Mortality Control Program for Economically Productive Age Group in Tribal Area of Melghat.","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":72564,"lead_sponsor_name":"MAHAN Trust","has_results":false},{"nct_id":"NCT03839979","title":"HCV Viral Hepatitis, Blood Sugar Level and Systolic Blood Pressure in Egypt","phase":"","overall_status":"COMPLETED","enrollment_count":71975,"lead_sponsor_name":"Cairo University","has_results":false},{"nct_id":"NCT06903897","title":"Social Needs Screening and Chronic Diseases Study (WE CARE)","phase":"NA","overall_status":"RECRUITING","enrollment_count":68000,"lead_sponsor_name":"University of Massachusetts, Worcester","has_results":false},{"nct_id":"NCT02468310","title":"Evaluating the Effects of SMS Text Messaging Support System Among Frontline Health Workers in Ghana","phase":"NA","overall_status":"COMPLETED","enrollment_count":65831,"lead_sponsor_name":"Hannah Brown Amoakoh","has_results":false},{"nct_id":"NCT06066541","title":"Social Norms, Messengers, and Processing Fluency to Increase Hypertension Medication Adherence","phase":"NA","overall_status":"COMPLETED","enrollment_count":65177,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":true},{"nct_id":"NCT04354350","title":"Replication of the ONTARGET Antihypertensive Trial in Healthcare Claims Data","phase":"","overall_status":"COMPLETED","enrollment_count":63744,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT06359873","title":"Left Atrial Enlargement: A Crucial Indicator for Identifying Atrial Fibrillation in Patients With Hypertension","phase":"","overall_status":"COMPLETED","enrollment_count":58427,"lead_sponsor_name":"The Second Affiliated Hospital of Chongqing Medical University","has_results":false},{"nct_id":"NCT06160921","title":"Prognostic Model of Hypertension","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"Xinjiang Medical University","has_results":false},{"nct_id":"NCT04212455","title":"A Cohort Study on Biomarkers of Hypertension in Guangdong Province(GDP Study)","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"Guangdong Provincial People's Hospital","has_results":false},{"nct_id":"NCT05030467","title":"Leveraging Electronic Health Record (EHR) Tools to Reduce Health Disparities for Patients With Uncontrolled Hypertension","phase":"NA","overall_status":"COMPLETED","enrollment_count":49210,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":true},{"nct_id":"NCT05126082","title":"Pediatric Blood Pressure Clinical Decision Support Tool (PedsBP CDS)","phase":"NA","overall_status":"COMPLETED","enrollment_count":41054,"lead_sponsor_name":"HealthPartners Institute","has_results":true},{"nct_id":"NCT02795910","title":"Integrated Primary Care for Diabetes and Cardiovascular Disease","phase":"NA","overall_status":"UNKNOWN","enrollment_count":40577,"lead_sponsor_name":"University of Sao Paulo General Hospital","has_results":false},{"nct_id":"NCT06683768","title":"A Real-world Study of the Safety of Hypertension Medication Therapy in Japanese Patients With Naïve Hypertension","phase":"","overall_status":"COMPLETED","enrollment_count":40563,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04354376","title":"Replication of the TRANSCEND Antihypertensive Trial in Healthcare Claims Data","phase":"","overall_status":"COMPLETED","enrollment_count":40048,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT05329714","title":"PVRI GoDeep Global Deep Phenotyping Meta-Registry for Pulmonary Hypertension","phase":"","overall_status":"RECRUITING","enrollment_count":40000,"lead_sponsor_name":"University of Giessen","has_results":false},{"nct_id":"NCT07048717","title":"The Mauritius and Rodrigues Non-Communicable Disease (NCD) Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":39082,"lead_sponsor_name":"Umeå University","has_results":false},{"nct_id":"NCT03549754","title":"iCaReMe Global Registry","phase":"","overall_status":"RECRUITING","enrollment_count":35000,"lead_sponsor_name":"AstraZeneca","has_results":false}],"total":50},"guidelines":[{"drug_id":"caduet","guideline_body":"FDA label","recommendation":"Amlodipine besylate tablets are indicated for the treatment of chronic stable angina.","line_of_therapy":"1L|2L|3L+|any","evidence_grade":"A","guideline_year":null},{"drug_id":"caduet","guideline_body":"FDA label","recommendation":"Amlodipine besylate tablets are indicated for the treatment of vasospastic angina (Prinzmetal's or variant angina).","line_of_therapy":"1L|2L|3L+|any","evidence_grade":"A","guideline_year":null},{"drug_id":"caduet","guideline_body":"FDA label","recommendation":"Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.","line_of_therapy":"1L|2L|3L+|any","evidence_grade":"A","guideline_year":null},{"drug_id":"caduet","guideline_body":"FDA label","recommendation":"Amlodipine besylate tablets are indicated for the treatment of chronic stable angina, vasospastic angina (Prinzmetal's or variant angina), and angiographically documented coronary artery disease in patients without heart failure or an ejection fraction < 40%.","line_of_therapy":"1L|2L|3L+|any","evidence_grade":"A","guideline_year":null},{"drug_id":"caduet","guideline_body":"FDA label","recommendation":"Amlodipine besylate tablets are indicated for the treatment of angiographically documented coronary artery disease in patients without heart failure or an ejection fraction < 40%.","line_of_therapy":"1L|2L|3L+|any","evidence_grade":"A","guideline_year":null},{"drug_id":"norvasc","guideline_body":"FDA label","recommendation":"Amlodipine besylate tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.","line_of_therapy":"1L|2L|3L+|any","evidence_grade":"1A","guideline_year":null},{"drug_id":"norvasc","guideline_body":"FDA label","recommendation":"Amlodipine besylate tablets are indicated for the treatment of chronic stable angina.","line_of_therapy":"1L|2L|3L+|any","evidence_grade":"1A","guideline_year":null},{"drug_id":"norvasc","guideline_body":"FDA label","recommendation":"Amlodipine besylate tablets are indicated for the treatment of vasospastic angina (Prinzmetal's or variant angina).","line_of_therapy":"1L|2L|3L+|any","evidence_grade":"1A","guideline_year":null},{"drug_id":"norvasc","guideline_body":"FDA label","recommendation":"Amlodipine besylate tablets are indicated for the treatment of angiographically documented coronary artery disease in patients without heart failure or an ejection fraction < 40%.","line_of_therapy":"1L|2L|3L+|any","evidence_grade":"1A","guideline_year":null}],"source":"Drug Landscape verified database"}